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ABSTRACT: An asymmetric catalytic reaction of hydroxyindoles with nitroalkenes leading to the Friedel−Crafts alkylation in
the carbocyclic ring of indole is presented. The method is based on the activating/directing effects of the hydroxy group situated
in the carbocyclic ring of the indole providing nitroalkylated indoles functionalizated at the C-4, C-5, and C-7 positions with high
yield, regio-, and enantioselectivity. The optically enriched nitroalkanes were transformed efficiently in optically enriched 2-
amino-1,1-diarylalkanes bearing a carbocyclic ring substituted indole.
■ INTRODUCTION
The arylethylamine moiety is present as a basic skeleton of a
series of compounds that exhibit significant pharmaceutical
properties.1 The installation of a second arene moiety at the
benzylic position of this arylethylamine scaffold leads to a new
structural motif, 2-amino-1,1-diarylalkane, with interesting
biological functions (Figure 1).2 Among them, the heteroaryl-
substituted derivatives represent an important class, particularly
those incorporating an indole3 core because of the importance
of this heterocyclic in medicinal4 and agrochemical chemistry5
and material science.6 Consequently, the enantioselective
synthesis of this kind of compounds constitutes a major
theme of recent research using asymmetric catalytic reactions
(ACR).7,8 Taking into consideration that nitroalkenes represent
a notable class of electrophiles for ACR,9 because of the
versatility of the resulting nitroalkanes as valuable intermediates
in organic synthesis,10 we envisioned a procedure for the
synthesis of 2-amino-1,1-diarylalkanes (Scheme 1). The
procedure involves the introduction of an indole framework
in the β-position of a nitrostyrene via a Friedel−Crafts
alkylation followed by reduction of the nitro group to amine.
The majority of methods on the enantioselective Friedel−
Crafts reaction of indoles involve the azole ring.8 This fact can
be explained by the inherent reactivity of indoles where the
azole ring possesses a high nucleophilicity, the C-3 position
being the most reactive. Additionally, different methodologies
to perform the asymmetric functionalization at the C-2 position
or the nitrogen atom have been described recently.11,12
In contrast, the functionalization of the carbocyclic ring is
more challenging, and only some nonenantioselective method-
ologies have been described.13 However, the enantioselective
functionalizations of positions C-4, C-5, C-6, and C-7 are
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Figure 1. Examples of biologically active 2-amino-1-aryl alkanes, 2-
amino-1,1-diarylalkanes, and hydroxyindoles.
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seldom studied in the literature. Therefore, the development of
methodologies that enable the asymmetric functionalization of
the carbocyclic ring of indoles is a great challenge in
asymmetric catalysis. We have recently presented a method-
ology for the organocatalytic enantioselective functionalization
of the carbocyclic ring of indoles using a hydroxy group as an
activating/directing group.14−16 Hydroxindoles, using bifunc-
tional organocatalysts, act as phenols, even when the positions
in the azole ring of indole remain unsubstituted. Given the
outstanding potential of chiral indoles and hydroxyindoles, the
development of new methodologies for the enantioselective
functionalization of indoles is of great interest.
In this Article, we described the enantioselective alkylation of
hydroxyindoles with β-nitrostyrenes. Several enantioselective
Friedel−Crafts reactions of indoles with nitroalkenes17,18 have
been described in the literature for the synthesis of chiral
triptamines (Scheme 1A). However, these examples are limited
to the functionalization of the azole ring. The corresponding
functionalization in the carbocyclic ring with nitroalkenes is
unprecedented, to the best of our knowledge (Scheme 1B).
The corresponding chiral nitroalkylated indoles in the
carbocyclic ring are significant because of the possibility of
reducing the nitro group and to synthesize 2-amino-1,1-
diarylalkanes.
■ RESULTS AND DISCUSSION
We started our studies with the Friedel−Crafts reaction of 4-
hydroxyindole (1a) with β-nitrostyrene (2a) in the presence of
chiral bifunctional organocatalysts19 in toluene as a solvent at
room temperature (Table 1). When quinine was used as a
catalyst, full conversion was observed after 24 h, and three
products were identified in the crude reaction mixture: the
corresponding alkylated products at C-5 position (3aa) and C-
7 position (3aa′) and the dialkylated hydroxyindole at C-5 and
C-7 positions (4), in a ratio 38:2:68 (3aa:3aa′:4) respectively.
We could isolate pure product 3aa in 18% yield as a racemate
(entry 1, Table 1). With catalyst II we could increase the yield
and the ee of product 3aa (entry 2), but both still were very
poor. When the thiourea derived from quinine III (entry 3) was
used as catalyst, the reaction was more selective toward product
3aa, which was gained with 56% yield and 31% ee. The use of
thiourea IV as catalyst (entry 4) gave worse results than did
thiourea III. However, the squaramide V proved to be superior
to the thiourea III, obtaining the best regioselectivity (63%
yield for 3aa) and enantioselectivity (83% ee, entry 5). While
squaramide VI (entry 7), introduced by Rawal,20 gave the best
enantiomeric excess (86% ee), and good yield (58%), it was not
sufficient for us. A solvent screening (entries 7−11) with
catalyst VI showed that chlorinated solvents performed the
reaction with the best enantioselectivities. Chloroform afforded
the product 3aa with the best enantiomeric excess (93% ee),
and the best yield (86%, entry 10). To avoid the polyalkylated
product 4 and increase the selectivity of product 3aa, we
increased the ratio between 1a and 2a (entry 12), obtaining a
slight decrease in the enantioselectivity. After, we screened the
catalyst loading, and we found that we could decrease the
catalyst loading to 2 mol % (entry 13) without compromising
the yield (80%) and enantiomeric excess (92% ee).
Furthermore, in these conditions, the dialkylation product 4
was not observed by 1H NMR in the reaction mixture.
Scheme 1. Enantioselective Functionalization of Indoles and
Hydroxyindoles with α,β-Unsaturated Nitroalkenes











1a I (10%) toluene 24 38:2:68 18 2
2a II
(10%)
toluene 23 53:10:37 25 9
3a III
(10%)
toluene 6 76:2:22 56 31
4a IV
(10%)
toluene 5 53:2:45 43 3
5a V
(10%)
toluene 2 90:2:8 63 83
6a V (5%) toluene 7 92:2:6 56 80
7a,b VI
(5%)
toluene 24 86:3:10 58 86
8a,b VI
(5%)
CH2Cl2 17 95:0:5 71 91
9a,b VI
(5%)
ClCH2CH2Cl 17 93:0:7 70 90
10a,b VI
(5%)
CHCl3 24 93:1:6 86 93
11a,b VI
(5%)
MTBE 48 55:31:14 25 n.d.g
12b,c VI
(5%)
CHCl3 8 98:0:2 93 90
13b,c VI
(2%)
CHCl3 22 100:0:0 80 92
14b,c VI
(1%)
CHCl3 22 100:0:0 70 90
aReaction conditions: 0.1 mmol of 1a, 0.1 mmol 2a, x mol % de
catalyst in 1 mL of solvent at rt. bThe temperature was 4 °C. cReaction
conditions: 0.15 mmol of 1a, 0.1 mmol of 2a, x mol % of catalyst in 1
mL of solvent. dDetermined by 1H NMR. eIsolated yield of 3aa.
fDetermined by chiral HPLC. gNot determined.
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With the optimized reaction conditions established, the
scope of the reaction was explored with respect to the 4-
hydroxyindole 1a and different β-nitrostyrenes 2 (Scheme 2). A
range of β-arylnitroalkenes were suitable for this reaction
obtaining good yields and enantioselectivities. Electron-with-
drawing (Br, CF3) and electron-donating groups (MeO, CF3O)
in para position were well tolerated. The presence of
substituents at ortho position (Me) led to an excellent
enantioselectivity (98% ee), although with a decrease in the
conversion (58% yield). When β-heteroarylnitroalkenes 2i and
2j were used, excellents yields and enantioselectivities were
obtained. Remarkably, when (E)-2-methoxy-4-(2-nitrovinyl)-
phenol 2h, with an hydroxyl group that may interfere in the
catalysis, was used as an electrophile, the corresponding
product 3ah was gained with excellent regio- and enantiose-
lectivity (94% ee). Finally, with ((1E,3E)-4-nitrobuta-1,3-dien-
1-yl)benzene 2k, product 3ak was obtained regioselectively
with 85% yield and 89% ee. This result is particularly
noteworthy, due to the possible regioisomers than can be
obtained in this reaction. From the point of view of the
nucleophile, hydroxyindole 1a can be alkylated at C-3, C-5, or
C-7, but we only observe alkylation at C-5. From the point of
view of the electrophile, we can have 1,4- or 1,6-addition, but
we only observed the 1,4-addition product. The absolute
configuration of product 3ab was determined by X-ray
analysis,21 and for the rest of compounds 3, we assumed a
uniform stereochemical mechanism.
After having proved the efficiency of our methodology for
the regio- and enantioselective Friedel−Crafts alkylation of 4-
hydroxyindole with nitroalkenes at the C-5 position, we
examined the scope of the reaction with indoles bearing a
hydroxy group in other positions of the carbocyclic ring. In this
way, we wanted to explore if we could achieve the
enantioselective functionalization of every position in this ring
by simply changing the position of the directing group.
Pleasingly, 5-hydroxyindole (1b) reacted with β-nitrostyrene
(2a) to give regioselectivity C-4 alkylated product 3ba with
good yield (79% yield) and high enantiocontrol (96% ee)
(Scheme 3). We carried out the reaction of 1b with several β-
aryl and β-heteroarylnitroalkenes obtaining high yields and
better enantioselectivities (up to 96% ee) than the reactions
with 1a. Moreover, the reaction with ((1E,3E)-4-nitrobuta-1,3-
dien-1-yl)benzene 2k procceded with excellent regioselectivity
(only one product was observed) and high enantioselectivity,
and product 3bk was gained with 95% yield and 89% ee.
Furthermore, the reaction was carried out with one β-
alkylnitroalkene. In this case, the reactivity was very low, and
we needed to increase the temperature to 50 °C and the
catalyst loading to 5 mol % for several days. In these conditions,
the reaction of 1b with (E)-(4-nitrobut-3-en-1-yl)benzene gave
regioselectively compound 3bl with moderate 44% yield, but
good enantioselectivity (87% ee). 5-Hydroxyindoles with alkyl
substituents at the pyrrole ring were also tested, and products
3ca and 3da were isolated in high yields with excellent
enantioselectivities (96% ee). In the reaction with 5-hydroxy-2-
methyl-indole 1d, we also observed the C-3 alkylated product
(15% yield) as a racemic mixture.
We also extend our methodology to 6-hydroxyindole 1e
(Scheme 4), which was regio- and enantioselectively alkylated
at the C-7 position with good yields and excellent enantiomeric
Scheme 2. Scope of the Friedel−Crafts Reaction with 4-
Hydroxyindole 1aa
aReaction conditions: 1a (0.15 mmol), 2 (0.1 mmol), and VI (2 mol
%) in 1 mL of CHCl3 at 4 °C. Isolated yields after column
chromatography. Enantiomeric excesses were determined by HPLC
using chiral stationary phase.
Scheme 3. Scope of the Friedel−Crafts Reaction with 5-
Hydroxyindole Derivativesa
aThe reaction was performed at 50 °C using 5 mol % of VI. Reaction
conditions: 1 (0.15 mmol), 2 (0.1 mmol), and VI (2 mol %) in 1 mL
of CHCl3 at 4 °C. Isolated yields after column chromatography.
Enantiomeric excesses were determined by HPLC using chiral
stationary phase.
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excess. 6-Hydroxyindole 1e proved to be less reactive than 1a
and 1b, and in general, we obtain lower conversions but the
products were obtained with excellent enantiomeric excesses.
Again, the conjugated nitrodiene derived from cinnamaldehyde
2k gave excellent regioselectivity and good ee value (89%),
although with a moderate yield (44%).
Finally, 7-hydroxyindole 1f was also tested under the
optimized reaction conditions (Scheme 5). Unfortunately, the
regioselectivity was low, obtaining a ratio (53:16:32),
determined by 1H NMR, of product alkylated at C-6 (3da),
at C-4 (3da′) and also the product of double alkylation 5, and
the enantiomeric excess of compound 3da was also very poor
(18% ee). We attribute these results to an interference between
the NH of the indole nucleous and the hydroxyl group.
To rationalize the observed regio- and enantioselectivity, we
propose a tentative transition state (Figure 2). The squaramide
acts as a bifunctional organocatalyst responsible for the
preorientation and the activation of the substrates. While the
nitroalkene is activated upon formation of hydrogen bonds
between nitro group and the squaramide,22 the hydroxyindole
undergoes nucleophilic activation by hydrogen bonding with
the tertiary amine moiety of the catalyst. This model explains
the ortho-regioselectivity for the nucleophiles and the S absolute
configuration of the final products. The influence of the
catalyst/OH-group interaction can be ascertained by the fact
that the 5-methoxyindole reacts very slowly under the
optimized reaction conditions (7% yield after 7 days), and
the corresponding Friedel−Crafts alkylation takes place at C-3.
To showcase the utility of our catalytic protocol for the
synthesis of chiral 2-amino-1,1-diarylalkanes, we performed first
the reaction of 5-hydroxyindole 1b and nitroalkene 2a at 1
mmol scale, obtaining the product 3ba with better yield (93%)
and the same ee (96%) as when the reaction was carried out
using 0.1 mmol of 2a (Scheme 6A). Next, we carried out the
selective reduction of the nitro group present in the alkylated
indoles 3ba and 3cc with NaBH4−NiCl2·6H2O, obtaining the
Scheme 4. Scope of the Friedel−Crafts Reaction with 6-
Hydroxyindole 1ea
aReaction conditions: 1e (0.15 mmol), 2 (0.1 mmol), and VI (2 mol
%) in 1 mL of CHCl3 at 4 °C. Isolated yields after column
chromatography. Enantiomeric ratios were determined by HPLC using
chiral stationary phase.
Scheme 5. Friedel−Crafts Alkylation of 7-Hydroxyindole 1f
with 2aa
aReaction conditions: 1f (0.15 mmol), 2a (0.1 mmol), and VI (2 mol
%) in 1 mL of CHCl3 at 4 °C. Enantiomeric excesses were determined
by HPLC using chiral stationary phase.
Figure 2. Proposed stereochemical model.
Scheme 6. Synthetic Transformationsa
aIsolated yields after column chromatography. Enantiomeric excesses
were determined by HPLC using chiral stationary phase.
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corresponding 2-amino-1,1-diarylalkanes with good yields and
preserving the ee, which were isolated as Boc-derivatives 6a and
6b (Scheme 6B). To eliminate the activating-directing hydroxy
group, we have also transformed compound 3ba in the
corresponding triflate 7. Triflates can be considered as
privileged synthetic intermediates for the synthesis of a large
number of molecules.23 So, triflate 7 was catalytically
hydrogenated with Pd/C at 1 atm, affording the corresponding
chiral 2-amino-1,1-diarylalkane 8 with a C-4 indolyl substituent
in good yield and without erosion in the enantiomeric excess
(Scheme 6C). In this procedure, the nitro group was
simultaneously reduced to the corresponding amine, which
was protected with AcCl to facilitate the isolation. With this
transformation, we demonstrate that the activating/directing
hydroxy group could be posteriorly removed obtaining the
chiral hydroxy group-free indole. Finally, we performed the
reaction of compound 3ba with methylvinylketone under acidic
catalysis to obtain product 9, following a classical Friedel−
Crafts alkylation at C-3 position of the indole scaffold, proving
that our method can provide highly functionalized chiral
indoles (Scheme 6D) and consequently 2-amino-1,1-diary-
lalkanes.
■ CONCLUSION
In summary, we have described an enantioselective synthesis of
2-amino-1,1-diarylalkanes bearing a carbocyclic ring substituted
indole through asymmetric catalytic reaction of hydroxyindoles
with nitroalkenes followed by reduction of the nitro group to
amine. The asymmetric catalytic reaction described here is the
first regio- and enantioselective alkylation in the carbocyclic
ring of indoles with nitroalkenes as electrophiles, which was
catalyzed by the commercially available Rawal squaramide VI
(2 mol % catalyst). Under our reaction conditions, hydrox-
yindoles react in the carbocyclic ring rather than in the azole
system because the hydroxy group acts as an activating group
but also directing group. We can introduce regioselectively the
electrophile at C-4, C-5, and C-7 with high levels of
enantioselectivity, by using 5-hydroxyindole, 4-hydroxyindole,
and 6-hydroxyindole, respectively.24 The selective reduction of
the nitro group present in the alkylated indoles was carried with
NaBH4−NiCl2·6H2O, obtaining the corresponding 2-amino-
1,1-diarylalkanes with good yield and preserving the ee. In
addition, we have performed the removal of the hydroxy group,
through the corresponding triflate, simultaneously to the
reduction of nitro group under mild reductive elimination
conditions in high overall yield. Studies to further extend the
scope of this reaction are currently underway in our laboratory.
■ EXPERIMENTAL SECTION
General Methods. Reactions were carried out in 5 mL vials under
air. Comercial reagents were used as purchased. Reactions were
monitored by TLC analysis using Merck Silica Gel 60 F-254 thin layer
plates. Flash column chromatography was performed on Merck silica
gel 60, 0.040−0.063 mm, and visualized using both a UV lamp (254
nm) and then a CAM solution (an aqueous solution of ceric
ammonium molybdate). Melting points were determined in capillary
tubes. NMR spectra were run at 300 MHz for 1H and 75 MHz for 13C
using residual nondeuterated solvent as internal standard (CHCl3, δ
7.26 and 77.00 ppm, respectively; MeOH, δ 3.34 ppm and δ 49.87
ppm, respectively). Chemical shifts are given in ppm. The carbon type
was determined by DEPT experiments. High-resolution mass spectra
(ESI) were recorded on a AB SCIEX Triple TOF spectrometer
equipped with an electrospray source with a capillary voltage of 4.5 kV
(ESI). Specific optical rotations were measured using sodium light (D
line 589 nm). Chiral HPLC analyses were performed in a
chromatograph equipped with a UV diode-array detector using
columns with chiral stationary phases from Daicel. Catalysts I, IV,
and VI were commercially available. Catalyst II was prepared from
quinine using Deng’s procedure.25 Catalyst III was prepared from
cinchonidine using Sooś’ procedure.26 Catalyst V was prepared from
quinine using Du’s procedure.27 Nitroalkenes 2a−j were commercially
available. Nitroalkenes 2l and 2k were prepared following a procedure
described by Lam.28 5-Hydroxy-1-methyl-indole 1c was synthesized
from 5-hydroxyindole 1b as described in the literature.29
General Procedure for the Nonenantioselective Friedel−
Crafts Reaction. In a 5 mL vial were placed the proper hydroxyindole
(1, 0.1 mmol), the proper nitroalkene (2, 0.1 mmol), and 1-(3,5-
bis(trifluoromethyl)phenyl)-3-(3-(dimethylamino)propyl) thiourea
(3.7 mg, 0.01 mmol). The mixture then was dissolved in toluene (1
mL), and it was stirred at room temperature for 24 h and purified by
column chromatography using hexane:AcOEt mixtures (95:5 to
70:30) to afford the product 3 as a racemic mixture.
General Procedure for the Enantioselective Friedel−Crafts
Reaction. In a 5 mL vial were placed the proper hydroxyindole (1,
0.15 mmol), the proper nitroalkene (2, 0.10 mmol), and Rawal
squaramide (VI, 0.84 mg, 0.002 mmol). The mixture then was
dissolved in CHCl3 (1 mL), and it was stirred at 4 °C until the
reaction was complete (TLC). Finally, the reaction mixture was
directly poured into the column chromatography, using hexane:AcOEt
mixtures (95:5 to 70:3) as eluent to afford the product 3 as an
enantioenriched mixture.
Specific Procedure for the Enantioselective Friedel−Crafts
Reaction with Nitroalkene 2l. In a 5 mL flask equipped with a
refrigerant were placed 5-hydroxyindole (1b, 0.15 mmol), (E)-(4-
nitrobut-3-en-1-yl)benzene (2l, 0.10 mmol), and Rawal Squaramide
(VI, 2.1 mg, 0.005 mmol). The mixture then was dissolved in CHCl3
(1 mL), and it was stirred at 50 °C until the reaction was complete
(TLC). Finally, the reaction mixture was directly poured into the
column chromatography, using hexane:AcOEt mixtures (95:5 to 70:3)
as eluent to afford the product 3al as an enantioenriched mixture.
Scope of the Reaction with 4-Hydroxyindole. (S)-5-(1-Phenyl-
2-nitroethyl)-1H-indol-4-ol (3aa). The product 3aa was obtained as a
dark oil (22.6 mg, 0.08 mmol, 80% yield). Enantiomeric excess (92%)
was determined by chiral HPLC (Chiralpak AD-H), hexane−iPrOH
70:30, 1.0 mL/min, major enantiomer tr = 14.55 min, minor
enantiomer tr = 16.10 min. [α]D
20 −79.2 (c = 0.55, CHCl3) (92%
ee); 1H NMR (300 MHz, CDCl3) δ 8.16 (s, 1H), 7.38−7.23 (m, 4H),
7.26−7.15 (m, 1H), 7.09 (dd, J = 3.3, 2.3 Hz, 1H), 6.93 (dd, J = 8.4,
0.7 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 6.49−6.40 (m, 1H), 5.36 (dd, J
= 8.7, 7.5 Hz, 1H), 5.18 (s, 1H), 5.17−5.03 (m, 2H); 13C NMR (75
MHz, CDCl3) 145.9 (C), 139.8 (C), 136.7 (C), 128.7 (CH), 127.8
(CH), 127.1 (CH), 123.8 (CH), 122.7 (CH), 118.0 (C), 114.8 (C),
104.6 (CH), 97.8 (CH), 78.5 (CH2), 43.2 (CH); HRMS (ESI) m/z:
[M + H]+ calcd for C16H15N2O3, 283.1077; found, 283.1083.
(S)-5-(1-(4-Bromophenyl)-2-nitroethyl)-1H-indol-4-ol (3ab). The
product 3ab was obtained as a yellow solid (35.0 mg, 0.097 mmol,
97% yield); mp 133−138 °C. Enantiomeric excess (87% and 90% after
crystallization) was determined by chiral HPLC (Chiralpak AD-H),
hexane−iPrOH 80:20, 1.0 mL/min, major enantiomer tr = 28.39 min,
minor enantiomer tr = 31.20 min. [α]D
20 −45.2 (c = 0.29, CHCl3) (87%
ee); 1H NMR (300 MHz, CDCl3) δ 8.19 (s, 1H), 7.41 (d, J = 8.5 Hz,
2H), 7.20 (d, J = 8.3 Hz, 2H), 7.14 (dd, J = 3.3, 2.3 Hz, 1H), 6.95 (dd,
J = 8.4, 0.9 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.46 (ddd, J = 3.2, 2.0,
0.9 Hz, 1H), 5.30 (dd, J = 9.0, 7.2 Hz, 1H), 5.13 (s, 1H), 5.11−5.03
(m, 2H); 13C NMR (75 MHz, CDCl3) δ 146.7 (C), 138.8 (C), 131.7
(CH), 131.2 (C), 129.4 (CH), 128.2 (C), 125.6 (CH), 120.9 (C),
115.0 (C), 112.9 (CH), 111.3 (CH), 100.6 (CH), 77.7 (CH2), 42.9
(CH); HRMS (ESI) m/z: [M + H]+ calcd for C16H14N2O3Br,
361.0182; found, 361.0192.
(S)-5-(1-(4-(Trifluoromethyl)phenyl)-2-nitroethyl)-1H-indol-4-ol
(3ac). The product 3ac was obtained as a dark oil (30.1 mg, 0.086
mmol, 86% yield). Enantiomeric excess (89%) was determined by
chiral HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min,
major enantiomer tr = 19.35 min, minor enantiomer tr = 17.81 min.
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[α]D
20 −55.2 (c = 0.65, CHCl3) (89% ee); 1H NMR (300 MHz,
CDCl3) δ 8.20 (s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.2 Hz,
2H), 7.15 (t, J = 2.8 Hz, 1H), 6.96 (dd, J = 8.4, 0.8 Hz, 1H), 6.86 (d, J
= 8.4 Hz, 1H), 6.46 (s, 1H), 5.40 (t, J = 8.1 Hz, 1H), 5.16 (s, 1H), 5.13
(d, J = 8.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) 145.9 (C), 144.1
(C), 136.8 (C), 129.3 (q, JC−F = 32.4 Hz, C), 128.2 (CH), 125.6 (q,
JC−F = 3.8 Hz, CH), 124.1 (CH), 124.4 (d, JC−F = 272.1 Hz, CF3),
122.7 (CH), 117.9 (C), 114.0 (C), 104.8 (CH), 97.7 (CH), 78.0
(CH2), 43.3 (CH);
19F NMR (282.4 MHz, CDCl3) δ −63.0 (s, CF3);
HRMS (ESI) m/z: [M + H]+ calcd for C17H14N2O3F3, 351.0951;
found, 351.0963.
(S)-5-(1-(4-Methoxyphenyl)-2-nitroethyl)-1H-indol-4-ol (3ad).
The product 3ad was obtained as a green solid (24.1 mg, 0.077
mmol, 77% yield); mp 169−173. Enantiomeric excess (86%) was
determined by chiral HPLC (Chiralpak AS-H), hexane−iPrOH 80:20,
1.0 mL/min, major enantiomer tr = 28.81 min, minor enantiomer tr =
41.49 min. [α]D
20 −48.9 (c = 1.16, MeOH) (86% ee); 1H NMR (300
MHz, CDCl3) δ 8.16 (s, 1H), 7.24 (d, J = 8.3 Hz, 2H), 7.13 (dd, J =
3.4, 2.4 Hz, 1H), 6.95 (dd, J = 8.5, 0.9 Hz, 1H), 6.89 (d, J = 8.4 Hz,
1H), 6.83 (d, J = 8.8 Hz, 2H), 6.47 (td, J = 2.3, 1.1 Hz, 1H), 5.28 (dd,
J = 8.7, 7.5 Hz, 1H), 5.14−5.06 (m, 2H), 5.02 (dd, J = 12.7, 8.9 Hz,
1H), 3.75 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.7 (C), 145.9
(C), 136.7 (C), 131.7 (C), 128.8 (CH), 123.8 (CH), 122.7 (CH),
118.1 (C), 115.1 (C), 114.2 (CH), 104.5 (CH), 97.9 (CH), 78.8
(CH2), 55.2 (CH3), 42.6 (CH); HRMS (ESI) m/z: [M + H]
+ calcd
for C17H17N2O4, 313.1183; found, 313.1192.
(S)-5-(1-(4-(Trifluoromethoxy)phenyl)-2-nitroethyl)-1H-indol-4-ol
(3ae). The product 3ae was obtained as a dark oil (34.8 mg, 0.095
mmol, 95% yield). Enantiomeric excess (88%) was determined by
chiral HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min,
major enantiomer tr = 17.28 min, minor enantiomer tr = 14.72 min.
[α]D
20 −39.2 (c = 0.91, CHCl3) (88% ee); 1H NMR (300 MHz,
CDCl3) δ 8.20 (s, 1H), 7.36 (d, J = 8.6 Hz, 2H), 7.15−7.06 (m, 3H),
6.96 (d, J = 8.5 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.57−6.40 (m, 1H),
5.35 (dd, J = 8.9, 7.3 Hz, 1H), 5.20 (s, 1H), 5.16−5.01 (m, 2H); 13C
NMR (75 MHz, CDCl3) δ 148.2 (C), 145.9 (C), 138.7 (C), 136.8
(C), 129.2 (CH), 124.0 (CH), 122.7 (CH), 121.1 (CH), 120.4 (d,
JC−F = 257.1 Hz, CF3), 118.0 (C), 114.3 (C), 104.7 (CH), 97.8 (CH),
78.3 (CH2), 42.9 (CH);
19F NMR (282.4 MHz, CDCl3) δ −58.3 (s,
CF3); HRMS (ESI) m/z: [M + H]
+ calcd for C17H14N2O4F3,
367.0900; found, 367.0916.
(S)-5-(1-(o-Tolyl)-2-nitroethyl)-1H-indol-4-ol (3af). The product
3af was obtained as a green solid (17.2 mg, 0.058 mmol, 58% yield);
mp 160−165. Enantiomeric excess (98%) was determined by chiral
HPLC (Chiralpak IC), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 4.88 min, minor enantiomer tr = 7.33 min. [α]D
20 −65.9
(c = 0.44, CHCl3) (98% ee);
1H NMR (300 MHz, CDCl3) δ 8.15 (s,
1H), 7.34 (d, J = 7.0 Hz, 1H), 7.23−7.11 (m, 4H), 6.89 (dd, J = 8.5,
0.7 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 6.48 (ddd, J = 3.0, 1.9, 0.8 Hz,
1H), 5.59−5.52 (m, 1H), 5.23 (s, 1H), 5.03−4.99 (m, 2H), 2.28 (s,
3H); 13C NMR (75 MHz, CDCl3) δ 146.0 (C), 137.6 (C), 137.1 (C),
136.7 (C), 131.1 (CH), 127.1 (CH), 126.1 (CH), 125.9 (CH), 123.8
(CH), 122.9 (CH), 117.8 (C), 113.9 (C), 104.6 (CH), 97.9 (CH),
77.9 (CH2), 38.9 (CH), 19.4 (CH3); HRMS (ESI) m/z: [M + H]
+
calcd for C17H17N2O3, 297.1234; found, 297.1225.
(S)-5-(1-(2,4-Dimethoxyphenyl)-2-nitroethyl)-1H-indol-4-ol (3ag).
The product 3ag was obtained as a dark oil (27.7 mg, 0.081 mmol,
81% yield). Enantiomeric excess (79%) was determined by chiral
HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 48.84 min, minor enantiomer tr = 30.42 min. [α]D
20
−73.2 (c = 0.55, CHCl3) (79% ee); 1H NMR (300 MHz, CDCl3) δ
8.12 (s, 1H), 7.12 (d, J = 8.3 Hz, 1H), 7.07 (dd, J = 3.3, 2.3 Hz, 1H),
6.98−6.89 (m, 2H), 6.53 (ddd, J = 3.1, 2.1, 0.8 Hz, 1H), 6.47−6.39
(m, 2H), 6.10 (s, 1H), 5.51 (t, J = 8.2 Hz, 1H), 5.19−4.95 (m, 2H),
3.87 (s, 3H), 3.74 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.0 (C),
157.1 (C), 146.5 (C), 136.7 (C), 128.3 (CH), 123.5 (CH), 121.5
(CH), 120.1 (C), 118.5 (C), 114.3 (C), 105.1 (CH), 104.4 (CH),
99.1 (CH), 99.0 (CH), 77.8 (CH2), 55.9 (CH3), 55.4 (CH3), 35.8
(CH); HRMS (ESI) m/z: [M + H]+ calcd for C18H19N2O5, 343.1288;
found, 343.1285.
(S)-5-(1-(4-Hydroxy-3-methoxyphenyl)-2-nitroethyl)-1H-indol-4-
ol (3ah). The product 3ah was obtained as a dark oil (27.2 mg, 0.075
mmol, 75% yield). Enantiomeric excess (94%) was determined by
chiral HPLC (Chiralpak AD-H), hexane−iPrOH 70:30, 1.0 mL/min,
major enantiomer tr = 27.50 min, minor enantiomer tr = 17.22 min.
[α]D
20 −78.2 (c = 0.47, CHCl3) (94% ee); 1H NMR (300 MHz,
CDCl3) δ 8.18 (bs, 1H), 7.12 (dd, J = 3.3, 2.4 Hz, 1H), 6.94 (dd, J =
8.5, 0.9 Hz, 1H), 6.88 (s, J = 8.4 Hz, 1H), 6.84 (m, 2H), 6.80 (s, 1H),
6.48 (ddd, J = 3.2, 2.1, 0.9 Hz, 1H), 5.53 (bs, 1H), 5.30−5.22 (m, 2H),
5.12−4.97 (m, 2H), 3.80 (s, 3H); 13C NMR (75 MHz, CDCl3) δ
146.7 (C), 145.9 (C), 144.8 (C), 136.7 (C), 131.6 (C), 123.9 (CH),
122.6 (CH), 120.1 (CH), 118.1 (C), 115.0 (C), 114.5 (CH), 110.8
(CH), 104.5 (CH), 98.0 (CH), 78.7 (CH2), 55.9 (CH3), 43.0 (CH);
HRMS (ESI) m/z: [M + H]+ calcd for C17H17N2O5, 329.1132; found,
329.1143.
(S)-5-(1-(Furan-2-yl)-2-nitroethyl)-1H-indol-4-ol (3ai). The prod-
uct 3ai was obtained as a yellow oil (24.5 mg, 0.09 mmol, 90% yield).
Enantiomeric excess (95%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 23.48 min, minor enantiomer tr = 25.76 min. [α]D
20
−52.14 (c = 0.66, CHCl3) (95% ee); 1H NMR (300 MHz, CDCl3) δ
7.191−7.151 (m, 3H), 7.02 (dt, J = 3.5, 1.1 Hz, 1H), 6.91 (dd, J = 5.1,
3.6 Hz, 1H), 6.67 (d, J = 8.6 Hz, 1H), 6.52 (ddd, J = 3.1, 2.1, 0.9 Hz,
1H), 5.72 (td, J = 7.7, 0.9 Hz, 1H), 5.38 (dd, J = 13.0, 7.8 Hz, 1H),
5.27 (dd, J = 13.0, 7.5 Hz, 1H), 4.82 (bs, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 152.8 (C), 146.1 (C), 142.1 (CH), 137.0 (C), 123.9 (CH),
123.0 (CH), 118.0 (C), 112.4 (C), 110.4 (CH), 107.1 (CH), 104.7
(CH), 98.1 (CH), 77.2 (CH2), 37.7 (CH); HRMS (ESI) m/z: [M +
H]+ calcd for C14H13N2O4, 273.0870; found, 273.0877.
(S)-5-(2-Nitro-1-(thiophen-2-yl)ethyl)-1H-indol-4-ol (3aj). The
product 3aj was obtained as a colorless oil (26.8 mg, 0.093 mmol,
93% yield). Enantiomeric excess (91%) was determined by chiral
HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 20.50 min, minor enantiomer tr = 34.27 min. [α]D
20
−0.15 (c = 1.45, CHCl3) (91% ee); 1H NMR (300 MHz, CDCl3) δ
8.21 (bs, 1H), 7.19 (dd, J = 5.1, 1.3 Hz, 1H), 7.12 (dd, J = 3.3, 2.4 Hz,
1H), 7.04−6.89 (m, 4H), 6.48 (dd, J = 2.8, 2.0 Hz, 1H), 5.69−5.51
(m, 1H), 5.32 (bs, 1H), 5.12−5.04 (m, 2H); 13C NMR (75.5 MHz,
CDCl3) δ 145.9 (C), 143.4 (C), 136.9 (C), 126.8 (CH), 124.9 (CH),
124.8 (CH), 124.0 (CH), 122.7 (CH), 118.0 (C), 114.4 (C), 104.3
(CH), 98.0 (CH), 79.2 (CH2), 39.1 (CH); HRMS (ESI) m/z: [M +
H]+ calcd for C14H13N2O3S, 289.0641; found, 289.0650.
(S,E)-5-(1-Nitro-4-phenylbut-3-en-2-yl)-1H-indol-4-ol (3ak). The
product 3ak was obtained as a colorless oil (26.3 mg, 0.085 mmol,
85% yield). Enantiomeric excess (89%) was determined by chiral
HPLC (Chiralpak AS-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 19.36 min, minor enantiomer tr = 21.63 min. [α]D
20
−17.79 (c = 1.04, CHCl3) (89% ee); 1H NMR (300 MHz, CDCl3) δ
8.21 (bs, 1H), 7.52−7.19 (m, 5H), 7.14 (dd, J = 3.3, 2.4 Hz, 1H),
7.06−6.94 (m, 2H), 6.57−6.54 (m, 2H), 6.53−6.50 (m, 1H), 5.38 (bs,
1H), 4.94−4.87 (m, 2H), 4.77 (ddd, J = 8.7, 4.3, 2.1 Hz, 1H); 13C
NMR (75.5 MHz, CDCl3) δ 146.1 (C), 136.8 (C), 136.7 (C), 132.2
(CH), 128.5 (CH), 127.6 (CH), 127.3 (CH), 126.4 (CH), 123.9
(CH), 123.1 (CH), 118.1 (C), 113.6 (C), 104.7 (CH), 97.8 (CH),
78.9 (CH2), 42.8 (CH); HRMS (ESI) m/z: [M + H]
+ calcd for
C18H17N2O3, 309.1234; found, 309.1237.
Scope of the Reaction with 5-Hydroxyindole. (S)-4-(1-Phenyl-
2-nitroethyl)-1H-indol-5-ol (3ba). The product 3ba was obtained as a
dark oil (0.1 mmol scale reaction, 22.4 mg, 0.079 mmol, 79% yield; 1
mmol scale reaction, 262.7 mg, 0.93 mmol, 93% yield). Enantiomeric
excess (96%) was determined by chiral HPLC (Chiralpak AD-H),
hexane−iPrOH 80:20, 1.0 mL/min, major enantiomer tr = 15.30 min,
minor enantiomer tr = 13.88 min. [α]D
20 −48.8 (c = 1.07, CHCl3) (96%
ee); 1H NMR (300 MHz, CDCl3) δ 8.07 (bs, 1H), 7.43−7.36 (m,
2H), 7.30−7.25 (m, 2H), 7.27−7.10 (m, 3H), 6.63 (d, J = 8.7 Hz,
1H), 6.51 (ddd, J = 3.2, 2.1, 1.0 Hz, 1H), 5.51−5.21 (m, 3H), 4.68 (bs,
1H); 13C NMR (75 MHz, CDCl3) δ 146.9 (C), 139.6 (C), 131.3 (C),
128.7 (CH), 128.4 (C), 127.6 (CH), 127.1 (CH), 125.4 (CH), 115.7
(C), 113.1 (CH), 111.1 (CH), 100.8 (CH), 77.9 (CH2), 43.3 (CH);
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HRMS (ESI) m/z: [M + H]+ calcd for C16H15N2O3, 283.1077; found,
283.1089.
(S)-4-(1-(4-Bromophenyl)-2-nitroethyl)-1H-indol-5-ol (3bb). The
product 3bb was obtained as a dark oil (34.3 mg, 0.095 mmol, 95%
yield). Enantiomeric excess (96%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 13.90 min, minor enantiomer tr = 11.78 min. [α]D
20
−49.1 (c = 1.12, CHCl3) (96% ee); 1H NMR (300 MHz, CDCl3) δ
8.11 (bs, 1H), 7.36 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 7.15
(dd, J = 3.2, 2.5 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 6.61 (d, J = 8.6 Hz,
1H), 6.48 (ddd, J = 3.0, 2.0, 0.8 Hz, 1H), 5.42−5.32 (m, 2H), 5.29−
5.18 (m, 1H), 4.77 (bs, 1H); 13C NMR (75 MHz, CDCl3) δ 146.7
(C), 138.8 (C), 131.7 (CH), 131.2 (C), 129.4 (CH), 128.2 (C), 125.6
(CH), 120.9 (C), 115.0 (C), 112.9 (CH), 111.3 (CH), 100.6 (CH),
77.7 (CH2), 42.9 (CH); HRMS (ESI) m/z: [M + H]
+ calcd for
C16H14N2O3Br, 361.0182; found, 361.0195.
(S)-4-(1-(4-Methoxyphenyl)-2-nitroethyl)-1H-indol-5-ol (3bd).
The product 3bd was obtained as a brown solid (22.5 mg, 0.072
mmol, 72% yield); mp 128−132 °C. Enantiomeric excess (94%) was
determined by chiral HPLC (Chiralpak AD-H), hexane−iPrOH 80:20,
1.0 mL/min, major enantiomer tr = 19.50 min, minor enantiomer tr =
22.35 min. [α]D
20 −11.3 (c = 0.67, MeOH) (94% ee); 1H NMR (300
MHz, CDCl3) δ 8.08 (bs, 1H), 7.32 (d, J = 8.6 Hz, 2H), 7.20−7.09
(m, 2H), 6.80 (d, J = 8.9 Hz, 2H), 6.64 (d, J = 8.5 Hz, 1H), 6.52 (ddd,
J = 3.0, 2.0, 0.9 Hz, 1H), 5.45−5.16 (m, 3H), 4.63 (bs, 1H), 3.73 (s,
3H); 13C NMR (75 MHz, CDCl3) δ 158.5 (C), 146.8 (C), 131.6 (C),
131.3 (C), 128.6 (CH), 125.4 (CH), 116.0 (C), 114.1 (CH), 113.2
(CH), 111.0 (CH), 100.9 (CH), 78.1 (CH2), 55.2 (CH3), 42.7 (CH);
HRMS (ESI) m/z: [M + H]+ calcd for C17H17N2O4, 313.1183; found,
313.1193.
(S)-4-(1-(Furan-2-yl)-2-nitroethyl)-1H-indol-5-ol (3bi). The prod-
uct 3bi was obtained as a colorless oil (22.6 mg, 0.083 mmol, 83%
yield). Enantiomeric excess (95%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 19.99 min, minor enantiomer tr = 16.94 min. [α]D
20
−32.11 (c = 1.06, CHCl3) (95% ee); 1H NMR (300 MHz, CDCl3) δ
8.15 (bs, 1H), 7.36−7.34 (m, 1H), 7.21−7.15 (m, 2H), 6.71 (d, J = 8.6
Hz, 1H), 6.39 (ddd, J = 3.1, 2.1, 0.9 Hz, 1H), 6.31 (dd, J = 3.3, 1.9 Hz,
1H), 6.16 (dt, J = 3.3, 0.9 Hz, 1H), 5.62 (t, J = 8.0 Hz, 1H), 5.33 (dd, J
= 13.1, 8.2 Hz, 1H), 5.07 (dd, J = 13.0, 7.0 Hz, 1H), 5.04 (bs, 1H); 13C
NMR (75.5 MHz, CDCl3) δ 152.3 (C), 147.1 (C), 141.9 (CH), 131.4
(C), 127.9 (C), 125.5 (CH), 113.1 (CH), 113.0 (C), 111.6 (CH),
110.6 (CH), 107.0 (CH), 100.6 (CH), 76.1 (CH2), 37.1 (CH);
HRMS (ESI) m/z: [M + H]+ calcd for C14H13N2O4, 273.0870; found,
273.0876.
(S)-4-(2-Nitro-1-(thiophen-2-yl)ethyl)-1H-indol-5-ol (3bj). The
product 3bj was obtained as a colorless oil (28.4 mg, 0.098 mmol,
98% yield). Enantiomeric excess (95%) was determined by chiral
HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 24.18 min, minor enantiomer tr = 17.67 min. [α]D
20
−10.61 (c = 0.15, CHCl3) (95% ee); 1H NMR (300 MHz, CDCl3) δ
8.12 (bs, 1H), 7.20−7.17 (m, 2H), 7.15 (t, J = 1.0 Hz, 1H), 7.02 (dt, J
= 3.5, 1.1 Hz, 1H), 6.91 (dd, J = 5.1, 3.6 Hz, 1H), 6.67 (d, J = 8.6 Hz,
1H), 6.52 (ddd, J = 3.1, 2.1, 0.9 Hz, 1H), 5.72 (td, J = 7.7, 0.9 Hz, 1H),
4.82 (bs, 1H); 13C NMR (75.5 MHz, CDCl3) δ 146.8 (C), 142.7 (C),
131.3 (C), 128.0 (C), 126.7 (CH), 125.5 (CH), 124.9 (CH), 124.7
(CH), 115.1 (C), 113.0 (CH), 111.5 (CH), 100.6 (CH), 78.4 (CH2),
39.0 (CH); HRMS (ESI) m/z: [M + H]+ calcd for C14H13N2O3S,
289.0641; found, 289.0650.
(S,E)-4-(1-Nitro-4-phenylbut-3-en-2-yl)-1H-indol-5-ol (3bk). The
product 3bk was obtained as a colorless oil (29.3 mg, 0.095 mmol,
95% yield). Enantiomeric excess (89%) was determined by chiral
HPLC (Chiralpak AS-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 66.76 min, minor enantiomer tr = 78.59 min. [α]D
20
−66.12 (c = 0.80, CHCl3) (89% ee); 1H NMR (300 MHz, CDCl3) δ
8.13 (s, 1H), 7.37−7.09 (m, 7H), 6.80−6.45 (m, 5H), 5.14 (dd, J =
14.1, 10.9 Hz, 1H), 4.95 (dt, J = 6.5, 5.0 Hz, 2H), 4.84 (s, 1H); 13C
NMR (75.5 MHz, CDCl3) δ 146.9 (C), 136.7 (C), 132.4 (CH), 131.4
(C), 128.4 (CH), 127.9 (C), 127.6 (CH), 126.4 (CH), 126.4 (CH),
125.5 (CH), 114.2 (C), 112.8 (CH), 111.1 (CH), 100.7 (CH), 77.9
(CH2), 42.2 (CH); HRMS (ESI) m/z: [M + H]
+ calcd for
C18H17N2O3, 309.1234; found, 309.1247.
(S)-4-(1-Nitro-4-phenylbutan-2-yl)-1H-indol-5-ol (3bl). The prod-
uct 3bl was obtained as a colorless oil (13.8 mg, 0.044 mmol, 44%
yield). Enantiomeric excess (87%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 12.79 min, minor enantiomer tr = 10.96 min. [α]D
20
−13.53 (c = 0.67, CHCl3) (87% ee); 1H NMR (300 MHz, CDCl3) δ
8.10 (bs, 1H), 7.25−7.12 (m, 5H), 7.12−7.04 (m, 2H), 6.67 (d, J = 8.6
Hz, 1H), 6.50 (ddd, J = 3.1, 2.0, 0.9 Hz, 1H), 5.03−4.83 (m, 2H), 4.66
(bs, 1H), 4.21−4.08 (m, 1H), 2.57−2.45 (m, 2H), 2.19−2.00 (m,
2H); 13C NMR (75.5 MHz, CDCl3) δ 147.3 (C), 141.7 (C), 131.3
(C), 128.3 (CH), 128.3 (CH), 125.8 (CH), 125.2 (CH), 114.9 (C),
112.8 (CH), 110.8 (CH), 101.0 (CH), 78.7 (CH2), 33.6 (CH2), 32.6
(CH2), 30.3 (CH); HRMS (ESI) m/z: [M + H]
+ calcd for
C18H19N2O3, 311.1390; found, 311.1397.
(S)-1-Methyl-4-(2-nitro-1-phenylethyl)-1H-indol-5-ol (3ca). The
product 3ca was obtained as a colorless oil (26.1 mg, 0.088 mmol,
88% yield). Enantiomeric excess (96%) was determined by chiral
HPLC (Chiralpak IC), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 7.17 min, minor enantiomer tr = 6.50 min. [α]D
20 −48.4
(c = 1.30, CHCl3) (96% ee);
1H NMR (300 MHz, CDCl3) δ 7.43−
7.36 (m, 2H), 7.34−7.15 (m, 4H), 7.08 (d, J = 8.6 Hz, 1H), 7.02 (d, J
= 3.1 Hz, 1H), 6.67 (d, J = 8.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H),
5.51−5.23 (m, 3H), 4.58 (s, 1H), 3.71 (s, 3H); 13C NMR (75.5 MHz,
CDCl3) δ 146.6 (C), 139.6 (C), 132.4 (C), 129.9 (CH), 128.9 (C),
128.7 (CH), 127.5 (CH), 127.0 (CH), 115.8 (C), 112.7 (CH), 109.4
(CH), 98.9 (CH), 77.8 (CH2), 43.2 (CH), 33.0 (CH3); HRMS (ESI)
m/z: [M + H]+ calcd for C17H17N2O3, 297.1234; found, 297.1239.
(S)-2-Methyl-4-(2-nitro-1-phenylethyl)-1H-indol-5-ol (3da). The
product 3da was obtained as a colorless oil (27.1 mg, inseparable
mixture of C-4 alkylated product:C-3 alkylated product (5.4:1 by 1H
NMR), 80% yield). Enantiomeric excess (96%) was determined by
chiral HPLC (Chiralcel OD-H), hexane−iPrOH 80:20, 1.0 mL/min,
major enantiomer tr = 13.47 min, minor enantiomer tr = 11.02 min.
[α]D
20 −64.1 (c = 1.43, CHCl3) (96% ee); 1H NMR (300 MHz,
CDCl3) δ 7.74 (s, 1H), 7.37 (d, J = 7.2 Hz, 2H), 7.22 (t, J = 3.7 Hz,
3H), 6.96 (d, J = 8.5 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 6.17 (s, 1H),
5.45−5.19 (m, 3H), 4.60 (s, 1H), 2.33 (s, 3H); 13C NMR (75.5 MHz,
CDCl3) δ 146.7 (C), 139.7 (C), 136.5 (C), 131.4 (C), 129.5 (C),
128.6 (CH), 127.5 (CH), 127.0 (CH), 114.9 (C), 111.5 (CH), 110.2
(CH), 98.8 (CH), 77.9 (CH2), 43.3 (CH), 13.8 (CH3). HRMS (ESI)
m/z: [M + H]+ calcd for C17H17N2O3, 297.1234; found, 297.1242.
Scope of the Reaction with 6-Hydroxyindole. (S)-7-(1-Phenyl-
2-nitroethyl)-1H-indol-6-ol (3ea). The product 3ea was obtained as a
dark oil (17.6 mg, 0.062 mmol, 62% yield). Enantiomeric excess (95%)
was determined by chiral HPLC (Chiralpak AS-H), hexane−iPrOH
90:10, 1.0 mL/min, major enantiomer tr = 42.21 min, minor
enantiomer tr = 49.20 min. [α]D
20 −67.5 (c = 0.92, CHCl3) (95%
ee); 1H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 7.41−7.25 (m, 6H),
6.94 (dd, J = 3.3, 2.4 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 6.41 (dd, J =
3.3, 2.0 Hz, 1H), 5.45−5.37 (m, 1H), 5.35−5.17 (m, 2H), 4.92 (s,
1H); 13C NMR (75 MHz, CDCl3) δ 149.0 (C), 138.7 (C), 135.7 (C),
129.1 (CH), 127.6 (CH), 127.4 (CH), 123.7 (CH), 123.3 (C), 120.8
(CH), 110.7 (CH), 107.6 (C), 102.9 (CH), 77.2 (CH2), 41.3 (CH);
HRMS (ESI) m/z: [M + H]+ calcd for C16H15N2O3, 283.1077; found,
283.1088.
(S)-7-(1-(4-Bromophenyl)-2-nitroethyl)-1H-indol-6-ol (3eb). The
product 3eb was obtained as a yellow solid (24.9 mg, 0.069 mmol,
69% yield); mp 190−194 °C. Enantiomeric excess (84%; 99% after
crystallization) was determined by chiral HPLC (Chiralpak AD-H),
hexane−iPrOH 80:20, 1.0 mL/min, major enantiomer tr = 8.97 min,
minor enantiomer tr = 10.10 min. [α]D
20 −0.17 (c = 1.085, CHCl3)
(84% ee); 1H NMR (300 MHz, CD3OD) δ 7.50−7.36 (m, 4H), 7.30
(d, J = 8.4 Hz, 1H), 7.09 (d, J = 3.2 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H),
6.36 (d, J = 3.2 Hz, 1H), 5.53−5.39 (m, 2H), 5.34 (dd, J = 11.5, 3.7
Hz, 1H); 13C NMR (75 MHz, CD3OD) δ 152.7 (C), 141.7 (C), 138.3
(C), 133.2 (CH), 131.9 (CH), 125.2 (CH), 124.6 (C), 122.4 (C),
122.0 (C), 112.1 (C), 109.3 (C), 103.7 (CH), 79.7 (CH2), 43.8 (CH);
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HRMS (ESI) m/z: [M + H]+ calcd for C16H14N2O3Br, 361.0182;
found, 361.0199.
(S)-7-(1-(4-(Trifluoromethyl)phenyl)-2-nitroethyl)-1H-indol-6-ol
(3ec). The product 3ec was obtained as a brown solid (27.0 mg, 0.077
mmol, 77% yield); mp 152−157. Enantiomeric excess (88%) was
determined by chiral HPLC (Chiralpak AD-H), hexane−iPrOH 80:20,
1.0 mL/min, major enantiomer tr = 6.58 min, minor enantiomer tr =
7.50 min. [α]D
20 −46.7 (c = 0.85, CHCl3) (88% ee); 1H NMR (300
MHz, CDCl3) δ 7.92 (s, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.3
Hz, 2H), 7.40 (d, J = 8.3 Hz, 1H), 7.04 (dd, J = 3.3, 2.4 Hz, 1H), 6.59
(d, J = 8.4 Hz, 1H), 6.45 (dd, J = 3.3, 1.9 Hz, 1H), 5.41−5.19 (m, 3H),
4.89 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 149.1 (C), 143.0 (C),
135.6 (C), 129.8 (JC−F = 32.3 Hz, C), 127.9 (CH), 125.9 (JC−F = 3.5
Hz, C), 123.89 (CH), 123.88 (d, JC−F = 272.0 Hz, CF3), 123.3 (C),
121.3 (CH), 110.7 (CH), 106.6 (C), 103.4 (CH), 77.12 (CH2), 41.5
(CH); 19F NMR (282.4 MHz, CDCl3) δ −63.11 (s, CF3); HRMS
(ESI) m/z: [M + H]+ calcd for C17H13N2O3F3, 351.0951; found,
351.0953.
(S)-7-(1-(4-Hydroxy-3-methoxyphenyl)-2-nitroethyl)-1H-indol-6-
ol (3eh). The product 3eh was obtained as a dark oil (12.2 mg, 0.037
mmol, 37% yield). Enantiomeric excess (90%) was determined by
chiral HPLC (Chiralpak IC), hexane−iPrOH 70:30, 1.0 mL/min,
major enantiomer tr = 7.78 min, minor enantiomer tr = 5.26 min. [α]D
20
−48.7 (c = 0.33, CHCl3) (90% ee); 1H NMR (300 MHz, CDCl3) δ
7.69 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 6.96−6.91 (m, 2H), 6.89 (d, J =
8.1 Hz, 1H), 6.85 (d, J = 2.0 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.39
(dd, J = 3.3, 2.0 Hz, 1H), 5.58 (s, 1H), 5.39 (dd, J = 8.9, 6.4 Hz, 1H),
5.22 (dd, J = 13.3, 8.9 Hz, 1H), 5.12 (dd, J = 13.2, 6.5 Hz, 1H), 4.93
(s, 1H), 3.78 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 149.2 (C), 147.7
(C), 145.7 (C), 136.1 (C), 130.9 (C), 124.1 (CH), 123.9 (C), 121.2
(CH), 119.7 (CH), 115.1 (CH), 111.1 (CH), 110.9 (CH), 103.2
(CH), 77.7 (CH2), 56.4 (CH3), 41.4 (CH); HRMS (ESI) m/z: [M +
H]+ calcd for C17H16N2O5, 329.1132; found, 329.1129.
(S)-7-(1-(Furan-2-yl)-2-nitroethyl)-1H-indol-6-ol (3ei). The prod-
uct 3ei was obtained as a colorless oil (26.9 mg, 0.099 mmol, 99%
yield). Enantiomeric excess (94%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 90:10, 1.0 mL/min, major
enantiomer tr = 25.78 min, minor enantiomer tr = 28.51 min. [α]D
20
−45.8 (c = 1.05, CHCl3) (94% ee); 1H NMR (300 MHz, CDCl3) δ
8.03 (bs, 1H), 7.43 (t, J = 0.9 Hz, 1H), 7.41 (dd, J = 5.4, 0.7 Hz, 1H),
7.02 (dd, J = 3.2, 2.4 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 6.45 (dd, J =
3.3, 2.0 Hz, 1H), 6.39 (dd, J = 3.3, 1.9 Hz, 1H), 6.31 (dt, J = 3.3, 0.9
Hz, 1H), 5.65 (ddd, J = 9.2, 6.1, 0.6 Hz, 1H), 5.22 (dd, J = 13.2, 9.2
Hz, 1H), 5.08 (bs, 1H), 4.97 (dd, J = 13.2, 6.1 Hz, 1H); 13C NMR
(75.5 MHz, CDCl3) δ 151.8 (C), 148.8 (C), 142.3 (CH), 135.3 (C),
123.8 (CH), 123.5 (C), 121.1 (CH), 111.0 (CH), 110.3 (CH), 107.7
(CH), 105.3 (C), 102.9 (CH), 75.4 (CH2), 35.1 (CH); HRMS (ESI)
m/z: [M + H]+ calcd for C14H13N2O4, 273.0870; found, 273.0877.
(S)-7-(2-Nitro-1-(thiophen-2-yl)ethyl)-1H-indol-6-ol (3ej). The
product 3ej was obtained as a colorless oil (26.6 mg, 0.092 mmol,
92% yield). Enantiomeric excess (94%) was determined by chiral
HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 11.71 min, minor enantiomer tr = 10.25 min. [α]D
20
−8.84 (c = 0.91, CHCl3) (94% ee); 1H NMR (300 MHz, CDCl3) δ
7.89 (bs, 1H), 7.42 (dd, J = 8.4, 0.6 Hz, 1H), 7.24 (dd, J = 5.1, 1.2 Hz,
1H), 7.06 (dt, J = 3.5, 1.2 Hz, 1H), 7.00 (dd, J = 3.2, 2.4 Hz, 1H), 6.97
(dd, J = 5.1, 3.5 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.45 (dd, J = 3.3,
2.0 Hz, 1H), 5.73−5.62 (m, 1H), 5.29 (dd, J = 13.3, 8.3 Hz, 1H), 5.17
(dd, J = 13.3, 6.6 Hz, 1H), 5.07 (bs, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 148.8 (C), 142.2 (C), 135.4 (C), 126.9 (CH), 125.5 (CH),
124.8 (CH), 123.8 (CH), 123.4 (C), 121.2 (CH), 110.6 (CH), 107.1
(C), 103.0 (CH), 77.7 (CH2), 37.1 (CH); HRMS (ESI) m/z: [M +
H]+ calcd for C14H13N2O3S, 289.0641; found, 289.0650.
(S,E)-7-(1-Nitro-4-phenylbut-3-en-2-yl)-1H-indol-6-ol (3ek). The
product 3ek was obtained as a colorless oil (13.6 mg, 0.044 mmol,
44% yield). Enantiomeric excess (89%) was determined by chiral
HPLC (Chiralpak AS-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 66.76 min, minor enantiomer tr = 78.59 min. [α]D
20
−66.12 (c = 0.80, CHCl3) (89% ee); 1H NMR (300 MHz, CDCl3) δ
8.25 (s, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.38−7.26 (m, 4H), 7.26−7.18
(m, 1H), 7.13−7.08 (m, 1H), 6.72−6.54 (m, 3H), 6.49 (dd, J = 3.2,
2.0 Hz, 1H), 5.09 (dd, J = 12.6, 8.4 Hz, 1H), 4.96 (dd, J = 12.5, 6.4 Hz,
1H), 4.93 (s, 1H), 4.82 (dt, J = 8.4, 6.2 Hz, 1H); 13C NMR (75.5
MHz, CDCl3) δ 149.3 (C), 136.3 (C), 135.5 (C), 132.5 (CH), 128.6
(CH), 127.9 (CH), 126.5 (CH), 125.9 (CH), 123.7 (CH), 123.2 (C),
120.8 (CH), 110.7 (CH), 106.1 (C), 103.2 (CH), 77.4 (CH2), 40.2
(CH); HRMS (ESI) m/z: [M + H]+ calcd for C18H17N2O3, 309.1234;
found, 309.1247.
Scope of the Reaction with 7-Hydroxyindole. (S)-6-(1-Phenyl-
2-nitroethyl)-1H-indol-7-ol (3fa). The product 3fa was obtained as a
dark oil (12.7 mg, 0.045 mmol, 45% yield). Enantiomeric excess (18%)
was determined by chiral HPLC (lux-amylose-1), hexane−iPrOH
80:20, 1.0 mL/min, major enantiomer tr = 11.50 min, minor
enantiomer tr = 12.55 min. [α]D
20 −10.2 (c = 0.26, CHCl3) (18%
ee); 1H NMR (300 MHz, CDCl3) δ 8.39 (s, 1H), 7.35−7.25 (m, 5H),
7.23 (d, J = 8.7 Hz, 1H), 7.14 (s, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.49−
6.45 (m, 1H), 5.27 (m, 2H), 5.09 (d, J = 7.9 Hz, 2H); 13C NMR (75
MHz, CDCl3) δ 139.2 (C), 139.1 (C), 129.3 (C), 129.2 (CH), 127.7
(CH), 127.6 (CH), 127.4 (C), 124.7 (CH), 119.2 (CH), 118.2 (C),
114.5 (CH), 103.0 (CH), 78.9 (CH2), 42.6 (CH); HRMS (ESI) m/z:
[M + H]+ calcd for C16H14N2O3, 283.1077; found, 283.1107.
Dialkylation Product When 4-Hydroxyindole Is Used.
Products 3aa′ and 4 were obtained as an unseparable mixture. Yet,
in some cases, 4 was obtained pure after column chromatography.
5,7-Bis(1-phenyl-2-nitroethyl)-1H-indol-4-ol (4). Dark oil; 1H
NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.35−7.17 (m, 10H),
6.99 (t, J = 2.9 Hz, 1H), 6.82 (s, 0.5H)*, 6.78 (s, 0.5H)*, 6.42 (ddd, J
= 3.1, 2.0, 1.0 Hz, 1H), 5.39−5.29 (m, 1H), 5.22 (s, 1H), 5.22−4.87
(m, 5H); 13C NMR (75 MHz, CDCl3) δ 145.9, 145.8*, 139.4, 139.3*,
138.2, 134.8, 129.4, 129.3*, 128.9, 128.8*, 128.12, 128.07*, 127.72,
127.71*, 127.6, 127.5*, 127.4, 127.3*, 124.3, 120.7, 120.2*, 118.8,
115.10, 115.06*, 114.9, 114.7*, 98.5, 78.82, 78.81*, 78.4, 78.3*, 44.64,
44.60*, 43.7, 43.3*; HRMS (ESI) m/z: [M + H]+ calcd for
C24H22N3O5, 432.1554; found, 432.1565. “*” indicates the presence
of rotamers.
Procedures and Characterization Data for Compounds 6.
tert-Butyl (S)-(2-(5-Hydroxy-1H-indol-4-yl)-2-phenylethyl)-
carbamate (6a). Compound 3ba (28.1 mg, 0.1 mmol) and NiCl2·
6H2O (23.8 mg, 0.1 mmol, 1 equiv) were placed in a 10 mL round
bottomed flask, and MeOH (1 mL) was added. After the suspension
was stirred, NaBH4 (18.9 mg, 0.5 mmol, 5 equiv) was added at 0 °C,
and the mixture was stirred at room temperature for 1.5 h, after which
the mixture was quenched with satd NH4Cl at 0 °C and extracted with
CH2Cl2. The organic layers were washed with brine and dried over
MgSO4. After being filtered and concentrated under vacuum, the crude
product was used in the next step as obtained. The crude amine and
Boc2O (21.8 mg, 0.1 mmol, 1 equiv) were placed in a 10 mL round
bottomed flask, and they were dissolved in CH2Cl2 (1 mL). Next,
Et3N (14 μL, 0.1 mmol, 1 equiv) was added. The mixture was stirred
overnight and after that was purified by flash chromatography on silica
gel using hexane/EtOAc mixtures (90:10 to 80:20) to afford the
product 6a (24.7 mg, 0.070 mmol) in 70% yield.
Enantiomeric excess (97%) was determined by chiral HPLC
(Chiralcel OD-H), hexane−iPrOH 90:10, 1.0 mL/min, major
enantiomer tr = 40.96 min, minor enantiomer tr = 51.38 min. Brown
oil; [α]D
20 −9.77 (c = 1.37, CHCl3) (97% ee); 1H NMR (300 MHz,
CD3OD) δ 7.43 (d, J = 7.5 Hz, 2H), 7.23 (t, J = 7.5 Hz, 2H), 7.19−
7.07 (m, 3H), 6.75 (d, J = 8.6 Hz, 1H), 6.31 (d, J = 3.1 Hz, 1H), 4.92
(m, 1H), 4.27−4.04 (m, 1H), 3.87 (dd, J = 13.3, 8.7 Hz, 1H), 1.39 (s,
9H); 13C NMR (75 MHz, CD3OD) δ 159.3 (C), 149.9 (C), 145.3
(C), 133.7 (C), 130.7 (C), 130.2 (CH), 129.8 (CH), 127.6 (CH),
126.5 (CH), 119.7 (C), 114.1 (CH), 112.1 (CH), 102.1 (CH), 80.8
(C), 46.4 (CH), 45.5 (CH2), 29.6 (CH3); HRMS (ESI) m/z: [M +
H]+ calcd for C21H25N2O3, 353.1865; found, 353.1862.
tert-Butyl (S)-(2-(6-Hydroxy-1H-indol-7-yl)-2-(4-(trifluoromethyl)-
phenyl)ethyl) Carbamate (6b). Compound 3cc (24.5 mg, 0.07
mmol) and NiCl2·6H2O (17.0 mg, 0.07 mmol, 1 equiv) were placed in
a 10 mL round bottomed flask, and MeOH (1 mL) was added. After
the suspension was stirred, NaBH4 (13.2 mg, 0.35 mmol, 5 equiv) was
added at 0 °C, and the mixture was stirred at room temperature for 1.5
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h, after which the mixture was quenched with satd NH4Cl at 0 °C and
extracted with CH2Cl2. The organic layers were washed with brine and
dried over MgSO4. After being filtered and concentrated under
vacuum, the crude product was used in the next step as obtained. The
crude amine and Boc2O (15.3 mg, 0.07 mmol, 1 equiv) were placed in
a 10 mL round bottomed flask, and they were disoslved in CH2Cl2 (1
mL). Next, Et3N (10 μL, 0.07 mmol, 1 equiv) was added. The mixture
was stirred overnight and after that was purified by flash
chromatography on silica gel using hexane/EtOAc mixtures (90:10
to 80:20) to afford the product 6b (18.2 mg, 0.043 mmol) in 62%
yield.
Enantiomeric excess (88%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 18.0 min, minor enantiomer tr = 20.76 min. Colorless
oil; [α]D
20 −36.7 (c = 0.56, CHCl3) (86% ee); 1H NMR (300 MHz,
CDCl3) δ 7.95 (s, 1H), 7.50 (d, J = 8.3 Hz, 3H), 7.42 (d, J = 8.3 Hz,
3H), 7.37 (d, J = 8.3 Hz, 1H), 6.93 (t, J = 2.8 Hz, 1H), 6.67 (d, J = 8.4
Hz, 1H), 6.41 (dd, J = 3.3, 1.9 Hz, 1H), 5.55 (s, 1H), 5.00−4.83 (m,
2H), 4.04 (m, 1H), 3.84 (ddd, J = 13.7, 8.4, 5.4 Hz, 1H), 1.36 (s,
10H); 13C NMR (75 MHz, CDCl3) δ 156.7 (C), 149.7 (C), 145.2
(C), 136.0 (C), 129.0 (q, JC−F = 32 Hz, C), 128.2 (CH), 125.7 (q, JC−F
= 3.4 Hz, CH), 124.1 (q, JC−F = 272.0 Hz, CF3), 123.5 (CH), 123.0
(C), 120.4 (CH), 111.1 (CH), 109.1 (C), 102.8 (CH), 80.1 (C) 43.0
(CH2), 42.2 (CH), 28.3 (CH3); HRMS (ESI) m/z: [M + H]
+ calcd
for C22H24F3N2O3, 421.1734; found, 421.1739.
Procedure and Characterization Data for Compound 7.
Compound 3ba (28.1 mg, 0.1 mmol) and 4-dimethylaminopyridine
(36.7 mg, 0.3 mmol, 3 equiv) were placed in a 10 mL round bottomed
flask. Next, the flask was purged with N2, and CH2Cl2 (2 mL) was
added. After 5 min, N-phenyl-bis(trifluoromethane sulfonimide (71.4
mg, 0.2 mmol, 2 equiv) was added, and the mixture was stirred at
room temperature. The reaction was monitored by thin layer
chromatography eluting with CH2Cl2. When the starting material
was consumed, H2O was added (5 mL), and the mixture was extracted
with EtOAc (3 × 20 mL). The combined organic layers were washed
with brine (30 mL) and dried under anhydrous Na2SO4. The organic
solvents were removed under reduced pressure, and the residue was
purified by column chromatography eluting with hexane:CH2Cl2
mixtures (50:50 to 30:70) to afford the triflated product 6 (38.8 mg,
0.084 mmol) in 84% yield.
(S)-4-(2-Nitro-1-phenylethyl)-1H-indol-5-yl Trifluoromethanesul-
fonate (7). Enantiomeric excess (96%) was determined by chiral
HPLC (Chiralpak AD-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 7.19 min, minor enantiomer tr = 8.19 min. Brown oil;
[α]D
20 −55.71 (c = 0.53, CHCl3) (96% ee); 1H NMR (300 MHz,
CDCl3) δ 8.40 (bs, 1H), 7.37−7.23 (m, 7H), 7.23−7.20 (m, 1H), 7.16
(d, J = 8.9 Hz, 1H), 6.34 (ddd, J = 3.2, 2.0, 0.9 Hz, 1H), 5.69 (dd, J =
8.1, 7.3 Hz, 1H), 5.43 (dd, J = 13.4, 8.4 Hz, 1H), 5.12 (dd, J = 13.4, 7.0
Hz, 1H); 13C NMR (75.5 MHz, CDCl3) δ 141.1 (C), 137.8 (C), 135.0
(C), 128.9 (CH), 127.4 (CH), 127.3 (CH), 127.0 (C), 126.9 (CH),
123.6 (C), 118.6 (q, J C−F = 320.2 Hz, C), 115.6 (CH), 112.1 (CH),
102.5 (CH), 77.0 (CH2), 41.3 (CH);
19F NMR (282 MHz, CDCl3) δ
−74.16 (s); HRMS (ESI) m/z: [M + H]+ calcd for C17H14F3N2O5S,
415.0570; found, 415.0577.
Procedure and Characterization Data for Compound 8.
Compound 7 (22.4 mg, 0.054 mmol) was placed in a 25 mL round
bottomed flask, which was purged with N2. Next, MeOH (3 mL) was
added, followed by 10% Pd/C (5 mg) and Et2NH (6.7 μL, 0.065
mmol, 1.2 equiv). The reaction vessel then was repeatedly purged with
H2 using a balloon and a needle as a vent. Finally, the reaction was
stirred at room temperature under H2 (1 atm, balloon). The reaction
was monitored by thin layer chromatography eluting with CH2Cl2.
When the reaction was complete, the suspension was passed through a
pad of Celite, and the organic solvents were removed under vacuum.
The residue then was placed in a 10 mL round bottomed flask, which
was purged with N2. CH2Cl2 was added (1.5 mL), and, when it was
dissolved, AcCl (5.8 μL, 0.081 mmol, 1.5 equiv) and Et3N (12.0 μL,
0.086 mmol, 1.6 equiv) were carefully added via syringe and the
mixture was stirred at room temperature until completion (TLC). The
reaction mixture was quenched by addition of H2O at 0 °C and
extracted three times with CH2Cl2. The combined organic layers were
washed with brine, dried over anhydrous MgSO4, and the filtrate was
concentrated to dryness in vacuo. The crude was purified by column
chromatography eluting with hexane:AcOEt mixtures (95:5 to 80:20)
to obtain the product 8 (11.3 mg, 0.041 mmol) in 75% yield.
(S)-N-(2-(1H-Indol-4-yl)-2-phenylethyl)acetamide (8). Enantio-
meric excess (93%) was determined by chiral HPLC (Chiralcel OD-
H), hexane−iPrOH 85:15, 1.0 mL/min, major enantiomer tr = 35.04
min, minor enantiomer tr = 38.99 min. Transparent oil; [α]D
20 −16.73
(c = 0.53, CHCl3) (93% ee);
1H NMR (300 MHz, CDCl3) δ 8.32 (s,
1H), 7.35−7.27 (m, 5H), 7.24−7.14 (m, 3H), 6.99 (d, J = 7.2 Hz,
1H), 6.57 (ddd, J = 3.1, 2.0, 0.9 Hz, 1H), 5.48 (s, 1H), 4.62 (t, J = 7.9
Hz, 1H), 4.10−3.96 (m, 2H), 1.86 (s, 3H); 13C NMR (75.5 MHz,
CDCl3) δ 170.1 (C), 142.0 (C), 136.0 (C), 135.0 (C), 128.6 (CH),
128.1 (CH), 127.5 (C), 126.6 (CH), 124.1 (CH), 122.1 (CH), 117.7
(CH), 110.0 (CH), 101.1 (CH), 47.9 (CH), 43.5 (CH2), 23.4 (CH3);
HRMS (ESI) m/z: [M + H]+ calcd for C18H19N2O, 279.1492; found,
279.1491.
Procedure and Characterization Data for Compound 9.
Compound 3ba (28.1 mg, 0.1 mmol) and racemic 1,1′-binaphthyl-
2,2′-diyl hydrogen phosphate (2.8 mg, 0.01 mmol, 0.1 equiv) were
placed in a 10 mL flask. The flask then was purged with N2, and
CH2Cl2 (1 mL) was added. After being stirred for 10 min,
methylvinylketone (9.8 μL, 0.12 mmol, 1.2 equiv) was added via
syringe. The mixture was stirred at room temperature for 24 h. Next,
H2O (5 mL) was added and the mixture was extracted with CH2Cl2 (3
× 20 mL). The combined organic layers were washed with brine and
dried over Na2SO4. Finally, the residue was purified by column
chromatography eluting with hexane:AcOEt mixtures (95:5 to 75:25),
and the C-3 alkylated product 9 (27.5 mg, 0.078 mmol) was obtained
in 78% yield.
(S)-4-(5-Hydroxy-4-(2-nitro-1-phenylethyl)-1H-indol-3-yl)butan-
2-one (9). Enantiomeric excess (96%) was determined by chiral HPLC
(Chiralpak AS-H), hexane−iPrOH 80:20, 1.0 mL/min, major
enantiomer tr = 19.52 min, minor enantiomer tr = 24.65 min.
Colorless oil; [α]D
20 −40.88 (c = 1.07, CHCl3) (96% ee); 1H NMR
(300 MHz, CDCl3) δ 7.96 (s, 1H), 7.34−7.19 (m, 5H), 7.13 (d, J =
8.5 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 6.65 (d, J = 8.6 Hz, 1H), 5.73 (t,
J = 7.4 Hz, 1H), 5.46 (dd, J = 12.9, 7.5 Hz, 1H), 5.31 (dd, J = 12.9, 7.3
Hz, 1H), 4.84 (s, 1H), 3.24 (td, J = 7.6, 3.9 Hz, 2H), 2.96−2.66 (m,
2H), 2.08 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 208.9 (C), 147.7
(C), 139.7 (C), 132.7 (C), 128.7 (CH), 127.5 (CH), 127.0 (CH),
126.4 (C), 124.3 (CH), 116.2 (C), 114.9 (C), 113.3 (CH), 111.5
(CH), 78.7 (CH2), 44.6 (CH2), 42.3 (CH), 29.8 (CH3), 21.8 (CH2);
HRMS (ESI) m/z: [M + Na]+ calcd for C20H20N2O4Na, 375.1315;
found, 375.1322.
Control Experiment with 5-Methoxyindole. In a 5 mL vial
were placed 5-methoxyindole (0.15 mmol), trans-β-nitrostyrene 2a
(0.10 mmol), and Rawal squaramide (VI, 0.84 mg, 0.02 mmol). The
mixture then was dissolved in CHCl3 (1 mL), and it was stirred at 4
°C until the reaction was complete (TLC). Finally, the reaction
mixture was directly poured into the column chromatography using
hexane:AcOEt mixtures (90:10 to 80:20) as eluent to afford the
product 10 as an enantioenriched mixture.
5-Methoxy-3-(1-phenyl-2-nitroethyl)-1H-indole (10). The product
10 was obtained as a colorless oil (3 mg, 0.007 mmol, 7% yield).
Enantiomeric excess (14%) was determined by chiral HPLC
(Chiralpak AD-H), hexane−iPrOH 90:10, 1.0 mL/min, major
enantiomer tr = 29.92 min, minor enantiomer tr = 44.34 min. The
HPLC conditions were previously described in the literature.30 1H
NMR (300 MHz, CDCl3) δ 7.97 (s, 1H), 7.33−7.24 (m, 5H), 7.22 (d,
J = 1.0 Hz, 1H), 7.01−6.99 (m, 1H), 6.86−6.80 (m, 2H), 5.12 (t, J =
7.5 Hz, 1H), 5.03 (dd, J = 12.2, 7.4 Hz, 1H), 4.92 (dd, J = 12.2, 8.4 Hz,
1H), 3.75 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 154.2 (C), 139.1
(C), 131.6 (C), 128.9 (CH), 127.8 (CH), 127.6 (CH), 126.6 (C),
122.3 (CH), 114.2 (C), 112.8 (CH), 112.1 (CH), 100.9 (CH), 79.5
(CH2), 55.8 (CH3), 41.5 (CH).
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